This segment focuses on the research and development of novel small molecule therapies targeting key pathways in immunology and inflammation. Ventyx Biosciences is actively involved in developing treatments for autoimmune diseases, inflammatory disorders, and related conditions. The company's lead product candidate, VTX958, a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor, is being evaluated in clinical trials for psoriasis, psoriatic arthritis, and Crohn's disease. Additionally, Ventyx is advancing VTX002, a sphingosine 1 phosphate receptor modulator, for ulcerative colitis. The company leverages advanced drug discovery techniques and precision medicine approaches to identify and develop targeted therapies with improved efficacy and safety profiles. Future opportunities include expanding the pipeline with innovative immunomodulatory agents and exploring new therapeutic applications for existing drug candidates.

This segment is dedicated to the development of CNS-penetrant NLRP3 inhibitors for neuroinflammatory conditions. Ventyx Biosciences is pioneering research into the role of NLRP3 inflammasome activation in neurodegenerative diseases, with a focus on developing therapies that can effectively target this pathway in the central nervous system. The company's lead CNS-penetrant NLRP3 inhibitor, VTX3232, is currently in Phase 2a clinical trials for early Parkinson's disease. This segment utilizes advanced medicinal chemistry and neuropharmacology techniques to design and optimize small molecule inhibitors with enhanced brain penetration and target engagement. Future opportunities include expanding the pipeline with additional CNS-targeted therapies and exploring new indications for VTX3232 in other neuroinflammatory disorders.